Stay updated with breaking news from Deborah Geraghty. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Two Global Phase 2 Clinical Trials, the Phase 2 portion of ACeD-it and Phase 2a SynCeD Studies, are Ongoing in Individuals with Celiac Disease New Data Presented During Digestive Disease Week® 2024
After decades of frustration and failed attempts, scientists might finally be on the cusp of developing therapies to restore immune ‘tolerance’ in conditions such as diabetes, lupus and multiple sclerosis. After decades of frustration and failed attempts, scientists might finally be on the cusp of developing therapies to restore immune ‘tolerance’ in conditions such as diabetes, lupus and multiple sclerosis.
CAMBRIDGE, Mass. & LAUSANNE, Switzerland, October 19, 2023--Anokion SA, a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, announced today that Deborah Geraghty, Ph.D., president and chief executive officer, will participate in the BofA Healthcare Trailblazers Private Company Conference on Thursday, October 26, 2023, in Boston, Mass.
Early-stage data support KAN-101, a liver-targeting drug that's vying to become the first treatment approved to treat celiac disease.
Phase 1b/2 Clinical Trial of KAN-101 in Patients with Celiac Disease Underway New Pharmacodynamic and Pharmacokinetic Data to be Presented Today During Digestive Disease Week 2023 Anokion SA